Press Release
Source: Viral Genetics, Inc.

Viral Genetics Expands Communications to Mark US Development Program

Azusa, California; September 8, 2006
Prior to embarking on a development program for VGV-1 in the United States, Viral Genetics is initiating a comprehensive communications program to highlight key development milestones and promote awareness of the Company and its products. Based on the results of completed studies of VGV-1 in South Africa and elsewhere, Viral Genetics will move forward with the development of VGV-1 in the United States. VGV-1 is a suspension of thymus nuclear protein that has been tested in several studies in HIV infected individuals.

The Company is now in the process of designing its US development strategy, which may include both preclinical research and clinical trials. The Company also intends to continue to support ongoing programs, including in South Africa.

“After many years of study, we are very excited to focus on moving towards regulatory approval through the Food and Drug Administration. Throughout this process, it is important that we gain greater recognition and understanding of the potential of our thymus nuclear protein technology,” said Haig Keledjian, CEO of Viral Genetics. “We are working closely with our Scientific Advisory Board to plan our development strategy and will provide more information over the next few months.”

To more effectively communicate study results and corporate achievements to the general public and media, and develop the Company’s profile within its industry, Viral Genetics has hired Ayars & Associates, a strategic public affairs firm. Ayars & Associates is redesigning the company’s public relations and communications programs to provide consistent corporate updates and gain greater exposure. A boutique firm based in Santa Barbara, California, Ayars & Associates also provides public relations services to several other healthcare firms.

In the fall, Viral Genetics will be presenting at a number of investor conferences. Beginning with the Edgewater Research LLC conference in San Diego, September 28 – 29, the company will also present at:

• Rodman & Renshaw 8th Annual Healthcare Conference: New York, November 6 – 8, 2006
• The PIPES Conference: New York, November 7 – 8, 2006
• The New York Society of Security Analysts Biotech Conference: New York, December 12-13, 2006

Prior to the conferences, the company will release additional presentation details.

About VGV-1
VGV-1 is a therapy based on thymus nuclear protein which is extracted from bovine thymus tissue. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. It was discovered by Dr. Zhabilov Sr. and has been studied in five human clinical trials for the treatment of HIV infection and AIDS.

About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com

For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Kathy Lane at 760-771-2236.

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but no limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service